Details for Patent: 7,375,111

Which drugs does patent 7,375,111 protect, and when does it expire?

Patent 7,375,111 protects CONTRAVE and is included in one NDA.

This patent has thirty-eight patent family members in twenty-three countries.

Summary for Patent: 7,375,111

Title:	Compositions for affecting weight loss
Abstract:	Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance .alpha.-MSH activity.
Inventor(s):	Weber; Eckard (San Diego, CA), Cowley; Michael Alexander (Portland, OR)
Assignee:	Orexigen Therapeutics, Inc. (San Diego, CA)
Application Number:	10/828,795
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,375,111
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form;

Drugs Protected by US Patent 7,375,111

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014		RX	Yes	Yes			Y

International Family Members for US Patent 7,375,111

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	388698
Australia	2004233846
Australia	2010221801